ALK and non-small cell lung carcinoma: In particular, patient-tailored therapies with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors have improved progression-free survival in patients with inoperable NSCLC [4–8].